In vivo characterization of endothelial cell activation in a transgenic mouse model of Alzheimer's disease

被引：35

作者：

Schultheiss C. ^{[1
]}

Blechert B. ^{[1
]}

Gaertner F.C. ^{[1
]}

Drecoll E. ^{[1
]}

Mueller J. ^{[1
]}

Weber G.F. ^{[2
]}

Drzezga A. ^{[1
]}

Essler M. ^{[1
,3
]}

机构：

[1] Nuklearmedizinische Klinik und Poliklinik, Technische Universität München, München

[2] Chirurgische Klinik, Technische Universität München, München

[3] Nuklearmedizinische Klinik, Technische Universität München, 81675, München

来源：

Angiogenesis | 2006年 / 9卷 / 2期

关键词：

Alzheimer's disease; Amyloid; Angiogenesis; Apoptosis; Endothelium; Integrins;

D O I：

10.1007/s10456-006-9030-4

中图分类号：

学科分类号：

摘要：

Alzheimer's disease (AD) is the most common cause of dementia worldwide. AD is characterized by an excessive cerebral amyloid deposition leading to degeneration of neurons and eventually to dementia. It has been shown by epidemiological studies that cardiovascular drugs with an anti-angiogenic effect can influence the outcome of AD patients. Therefore, it has been speculated that in AD angiogenesis in the brain vasculature may play an important role. Here we report that in the brain of APP23 mice - a transgenic model of AD - after deposition of amyloid in blood vessels endothelial cell activation occurs in an age-dependent manner. Amyloid deposition is followed by the expression of β3-integrin, a specific marker molecule of activated endothelium. The β3-integrin expression is restricted to amyloid-positive vessels. Moreover, homogenates of the brains of APP23 mice induced the formation of new vessels in an in vivo angiogenesis assay. Vessel formation could be blocked by the VEGF antagonist SU 4312 as well as by statins, suggesting that these drugs may interfere with endothelial cell activation in AD. In conclusion our results indicate that amyloid deposition in the vasculature leads to endothelial cell apoptosis and endothelial cell activation, which can be modulated by anti-angiogenic drugs. © Springer 2006.

引用

页码：59 / 65

页数：6

共 17 条

[1]

Vaganuccui A.H., Li W.W., Alzheimer's disease and angiogenesis, The Lancet, 361, pp. 605-608, (1994)

[2]

In't Veld B.A., Ruitenberg A., Hofmann A., Et al., Nonsteroidal antiinflammatory drugs and the risk of Alzheimer's disease, N Engl J Med, 345, pp. 1515-1521, (2003)

[3]

Wolozin B., Kellman W., Ruosseau P., Et al., Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors, Arch Neurol, 57, pp. 1439-1443, (2000)

[4]

Selkoe D.J., Translating cell biology into therapeutic advances in Alzheimer's disease, Nature, 399, SUPPL., (1999)

[5]

McGeer P.L., Schulzer M., McGeer E.G., Arthritis and antiinflammatory agents as possible protective factors for Alzheimer's disease: A review of 17 epidemiologic studies, Neurology, 47, pp. 425-432, (1996)

[6]

Liu F., Lau B.H., Peng Q., Shah V., Pycnogenol protects vascular endothelial cells from beta-amyloid-induced injury, Biol Pharm Bull, 23, pp. 735-737, (2000)

[7]

Gentile M.T., Vecchione C., Maffei A., Et al., Mechanisms of soluble beta-amyloid impairment of endothelial function, J Biol Chem, 279, pp. 48135-48142, (2004)

[8]

Kalaria R.N., Cohen D.L., Premkumar D.R., Et al., Vascular endothelial growth factor in Alzheimer's disease and experimental cerebral ischemia Brain, Res Mol Brain Res, 62, pp. 101-105, (1998)

[9]

Yang S.P., Bae D.G., Kang H.J., Et al., Co-accumulation of vascular endothelial growth factor with beta-amyloid in the brain of patients with Alzheimer's disease, Neurobiol Aging, 25, pp. 283-290, (2004)

[10]

Tarkowski E., Issa R., Sjogren M., Et al., Increased intrathecal levels of the angiogenic factors VEGF and TGF-beta in Alzheimer's disease and vascular dementia, Neurobiol Aging, 23, pp. 237-243, (2002)

← 1 2 →